Profile and Predictors of Blood Tumor Mutational Burden in Advanced Hepatocellular Carcinoma

Joseph W. Franses, Mir Lim, Adam M. Burgoyne, Kabir Mody, Jochen Lennerz, Jeremy Chang, Robin Imperial, Stacey N. Dybel, Thi M. Dinh, Jude Masannat, Caroline M. Weipert, David Hsiehchen

Research output: Contribution to journalArticlepeer-review

Abstract

Advanced hepatocellular carcinoma (HCC) is responsive to immune checkpoint inhibitors, but there are currently no known biomarkers to predict treatment benefit. Blood TMB (bTMB) estimation via circulating tumor DNA (ctDNA) profiling can provide a convenient means to estimate HCC TMB. Here we provide the first landscape of bTMB in advanced HCC using a commercially available next-generation sequencing assay, show that it is approximately three times as high as matched tissue TMB, and show that bTMB correlates with NAFLD cirrhosis etiology and the presence of genomic alterations in HTERT and TP53. These results lay the foundation for subsequent studies evaluating bTMB as an immune therapy predictive biomarker in HCC.

Original languageEnglish (US)
Pages (from-to)E908-E911
JournalOncologist
Volume27
Issue number11
DOIs
StatePublished - Nov 2022

Keywords

  • hepatocellular carcinoma
  • liquid biopsy
  • tumor mutational burden

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Profile and Predictors of Blood Tumor Mutational Burden in Advanced Hepatocellular Carcinoma'. Together they form a unique fingerprint.

Cite this